Literature DB >> 15001622

Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome.

Evanthia Diamanti-Kandarakis1, Chryssa Kouli, Krystallenia Alexandraki, Giovanna Spina.   

Abstract

Insulin resistance is a common metabolic feature of polycystic ovary syndrome (PCOS). In this study, we examined the validity of the mathematical indices [the quantitative insulin sensitivity check index (QUICKI) and the homeostasis model of assessment (HOMA)] that calculate insulin sensitivity and their correlation to glucose utilization with the insulin infusion rate in 40 mU/m(2).min by the euglycemic clamp (M) in women with PCOS. We studied 59 women with PCOS (20 lean, 16 overweight, and 23 obese subjects). Euglycemic clamp testing was performed, and QUICKI, HOMA, total testosterone, fasting insulin, fasting glucose, and glucose-to-insulin ratio were estimated. No difference was found in testosterone and glucose levels among the three groups. Lean or overweight women compared with obese women differed in insulin levels, glucose-to-insulin ratio, QUICKI, and HOMA (P < 0.01). No statistical difference was found between lean and overweight women in the above parameters. M differed when lean women were compared with overweight (P < 0.002) or obese women (P < 0.0001); however, no statistical difference was observed between overweight and obese women. No significant correlation was found between M and QUICKI or HOMA. We conclude that mathematical indices should be applied with caution in different insulin-resistant populations and should not be considered a priori equivalent to the euglycemic clamp technique.

Entities:  

Mesh:

Year:  2004        PMID: 15001622     DOI: 10.1210/jc.2003-031205

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

Review 2.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 3.  CLINICAL PRACTICE. Polycystic Ovary Syndrome.

Authors:  Christopher R McCartney; John C Marshall
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

Review 4.  Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index.

Authors:  R A Condorelli; A E Calogero; M Di Mauro; L M Mongioi'; R Cannarella; G Rosta; S La Vignera
Journal:  J Endocrinol Invest       Date:  2017-09-23       Impact factor: 4.256

Review 5.  Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.

Authors:  Laura C Torchen
Journal:  Curr Diab Rep       Date:  2017-11-11       Impact factor: 4.810

Review 6.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 7.  Insulin resistance in PCOS.

Authors:  Evanthia Diamanti-Kandarakis
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

8.  Relationship between surrogate estimates and direct measurement of insulin resistance in women with polycystic ovary syndrome.

Authors:  M H Dahan; F Abbasi; G Reaven
Journal:  J Endocrinol Invest       Date:  2019-01-30       Impact factor: 4.256

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Association study of AMP-activated protein kinase subunit genes in polycystic ovary syndrome.

Authors:  Kari Sproul; Michelle R Jones; Ricardo Azziz; Mark O Goodarzi
Journal:  Eur J Endocrinol       Date:  2009-07-02       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.